Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy

• DOI: 10.3389/fphar.2024.1340764
• Publication Date: 2024-01-24T04:11:40Z
• Authors: Lu-Qi Cao; Haidong Sun; Yuhao Xie; Harsh Patel; Letao Bo; Hanli Lin; Zhe-Sheng Chen
• Keywords: Targeted Therapy; Hormone Therapy

Breast cancer, a complex and varied disease, has four distinct subtypes based on estrogen receptor human epidermal growth factor 2 (HER2) levels, among which significant subtype known as HR+/HER2-breast cancer that spurred numerous research. The prevalence of breast cancer-related death are the most serious threats to women’s health worldwide. Current progress in treatment strategies for encompasses targeted therapy, endocrine genomic immunotherapy, supplementing traditional methods like surgical resection radiotherapy. This review article summarizes current epidemiology introduces classification commonly used methods. mechanisms action various drugs, including therapy drugs hormone their potential synergistic effects deeply discussed. In addition, clinical trials these have been completed or still included.